Back to Report Store Home

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 – Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

  • Published: Dec-2016
  • Report Code: GBIHC426MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 9

2.1 Disease Introduction 9

2.2 Epidemiology 10

2.3 Symptoms 11

2.4 Etiology and Pathophysiology 11

2.5 Diagnosis 13

2.5.1 Office or Clinic Blood Pressure Monitoring 14

2.5.2 Automated Office Blood Pressure Measurement 14

2.5.3 Ambulatory Blood Pressure Monitoring 15

2.5.4 Home Blood Pressure Monitoring 15

2.5.5 Miscellaneous Methods 15

2.5.6 Diagnosis of Target Organ Damage 15

2.5.7 Diagnosis of Hypertension in Pregnancy 15

2.6 Prognosis 16

2.7 Disease Stage 17

2.8 Treatment Options 17

2.8.1 Treatment Algorithm 17

2.8.2 Pharmacological Treatment 18

2.8.3 Non-pharmacological Treatment 22

3 Marketed Products 24

3.1 Angiotensin II Receptor Antagonists 24

3.1.1 Losartan – Merck & Co 24

3.1.2 Olmesartan – Daiichi Sankyo 26

3.1.3 Olmesartan + Amlodipine + Hydrochlorothiazide – Daiichi Sankyo 27

3.1.4 Valsartan – Novartis 28

3.1.5 Telmisartan – Boehringer Ingelheim 29

3.1.6 Azilsartan Medoxomil – Takeda 30

3.2 Calcium Channel Blockers 31

3.2.1 Amlodipine – Pfizer 31

3.3 Renin Inhibitors 32

3.3.1 Aliskiren – Novartis 32

3.4 Angiotensin Converting Enzyme Inhibitors 33

3.4.1 Ramipril – Sanofi 33

3.5 Beta Blockers 34

3.5.1 Carvedilol – GlaxoSmithKline 34

3.6 Multiple Drug Class Combinations 35

3.6.1 Perindopril Arginine + Amlodipine Besylate – Les Laboratoires Servier 35

3.6.2 Amlodipine + Valsartan – Novartis 35

3.7 Comparative Efficacy and Safety of Marketed Products 36

4 Pipeline Analysis 39

4.1 Overview 39

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 40

4.3 Pipeline by Molecular Target 41

4.4 Promising Pipeline Candidates 44

4.4.1 CS-3150 44

5 Clinical Trial Analysis 46

5.1 Failure Rate 46

5.1.1 Overall Failure Rate 46

5.1.2 Failure Rate by Phase and Molecule Type 47

5.1.3 Failure Rate by Phase and Molecular Target 48

5.2 Clinical Trial Duration 49

5.2.1 Clinical Trial Duration by Molecule Type 49

5.2.2 Clinical Trial Duration by Molecular Target 50

5.3 Clinical Trial Size 51

5.3.1 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 51

5.3.2 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 53

5.4 Competitive Clinical Trials Metrics Analysis 55

6 Multi-Scenario Forecast 57

6.1.1 Geographical Markets 57

6.1.2 Asia-Pacific Market 57

6.2 India 60

6.2.1 Treatment Use Patterns 60

6.2.2 Annual Cost of Therapy 61

6.2.3 Market Size 61

6.3 China 62

6.3.1 Treatment Use Patterns 62

6.3.2 Annual Cost of Therapy 63

6.3.3 Market Size 64

6.4 Australia 65

6.4.1 Treatment Use Patterns 65

6.4.2 Annual Cost of Therapy 66

6.4.3 Market Size 67

6.5 South Korea 68

6.5.1 Treatment Usage Patterns 68

6.5.2 Annual Cost of Therapy 70

6.5.3 Market Size 71

6.6 Japan 71

6.6.1 Treatment Use Patterns 71

6.6.2 Annual Cost of Therapy 72

6.6.3 Market Size 73

7 Drivers and Barriers 75

7.1 Drivers 75

7.1.1 Increasing Aging Populations to Increase Prevalence 75

7.1.2 Increasing Overweight and Obese Population 75

7.1.3 Increase in Daily Sodium Intake 75

7.1.4 Sedentary Lifestyle or Less Physical Activity 76

7.1.5 High Prevalence of Smoking and Alcoholism 76

7.1.6 Diversified Healthcare Reform to Boost Market Growth 77

7.2 Barriers 77

7.2.1 Weak Pipeline and Widespread Usage of Generic Drugs 77

7.2.2 Non-pharmacological First-Line Treatment 77

7.2.3 Lack of Awareness of the Disease Condition 77

8 Deals and Strategic Consolidations 78

8.1 Licensing Deals 78

8.1.1 Deals by Region and Value 78

8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 79

8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 80

8.1.4 Key Licensing Deals 82

8.2 Co-development Deals 83

8.2.1 Deals by Region and Value 84

8.2.2 Deal Value by Stage of Development, Molecule Type, and Molecular Target 85

8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 85

8.2.4 Key Co-development Deals 86

9 Appendix 88

9.1 All Pipeline Drugs by Stage of Development 88

9.1.1 Discovery 88

9.1.2 Preclinical 88

9.1.3 Investigational New Drug/ Clinical Trial Authorization-Filed 90

9.1.4 Phase I 91

9.1.5 Phase II 92

9.1.6 Phase III 92

9.1.7 Pre-registration 94

9.2 Market Forecasts to 2022 94

9.2.1 Asia-Pacific 94

9.2.2 India 95

9.2.3 China 95

9.2.4 Australia 96

9.2.5 South Korea 96

9.2.6 Japan 97

9.3 Reference 97

9.4 Abbreviations 106

9.5 Research Methodology 108

9.5.1 Secondary Research 108

9.5.2 Marketed Product Profiles 108

9.5.3 Late-Stage Pipeline Candidates 108

9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 109

9.5.5 Product Competitiveness Framework 109

9.5.6 Pipeline Analysis 109

9.5.7 Forecasting Model 110

9.5.8 Deals Data Analysis 111

9.6 Contact Us 111

9.7 Disclaimer 111

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards